TCN1 expression in colon cancer and metastatic tumor tissues and its relationship with clinical features and prognosis

doi:10.3877/cma.j.issn.1674-0785.2021.11.018

Abstract

Abstract:

Objective

To reveal the TCN1 expression status in colon cancer tissues, adjacent control tissues, and metastatic tumor tissues and discuss the relationship of TCN1 expression level with the clinical characteristics and prognosis of colon cancer patients.

Methods

A total of 212 patients with colon cancer who underwent tumor resection were enrolled from January 2013 to June 2014 at the Second Department of Surgery of Fourth Hospital of Hebei Medical University. Surgically resected specimens were selected to make pathological chips and for immunohistochemistry. The TCN1 expression colon adenocarcinoma (COAD) bioinformatics database was selected and bioinformatics technology was used to verify the TCN1 mRNA expression level in colon cancer tissues. Follow-up data was employed to discuss the relationship between the expression level of TCN1 and clinical characteristics and prognosis of colon cancer.

Results

The positive expression rate of TCN1 in colon cancer tissues was 71.70% (152/212), which was significantly higher than that in adjacent tissues (3.77% [8/212]; P＜0.001). Bioinformatics analysis of the COAD database verified that TCN1 was highly expressed in colon cancer tissues at the mRNA level (colon cancer tissues: 5.829±3.336 vs normal colon mucosal tissues:1.298±1.085). The positive expression rate of TCN1 in lung metastasis tissue was 100%, which was consistent with the expression level in primary colon cancer. After neoadjuvant chemotherapy, the expression of TCN1 decreased (5.29±3.06 vs 3.88±1.78, P=0.009). The expression level of TCN1 was positively correlated with clinical stage and caner location, and the positive expression rate increased with advanced stage (P＜0.05). In contrast, TCN1 expression level was not related with sex (P=0.601), age (P=0.376), history of diseases of the digestive system (P=0.240), smoking history (P=0.068), drinking history (P=0.512), or pathologic type (P=0.319). Univariate Cox regression analysis showed that M stage (P=0.035), TNM stage (P=0.014), and TCN1 expression level (P=0.042) were prognostic factors for colon cancer. The 5-year survival rate was 64.62% in the whole cohort, 76.67% in the TCN1 negative expression group, and 59.87% in the positive expression group (P=0.031); there was a significant difference between the two group (P=0.031). Cox multiple regression analysis showed that M stage (P=0.044) and TCN1 expression status (P=0.047) were independent prognostic factors.

Conclusion

TCN1 is highly expressed in colon cancer and colon cancer metastatic tissues, and the expression level is related to prognosis and can be used as a prognostic biomarker.

Key words: Colon cancer, Transcobalamin 1, Prognosis, Clinical features

Guangjie Liu, Miao Yu, Juan Zhang, Hongqing Ma, Xuhua Hu, Mingkun Deng, Hongmei Pan, Guiying Wang. TCN1 expression in colon cancer and metastatic tumor tissues and its relationship with clinical features and prognosis[J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(11): 904-910.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2021.11.018

https://zhlcyszz.cma-cmc.com.cn/EN/Y2021/V15/I11/904

Figures/Tables 5

References 22

1	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2	Shitara K, Yamanaka T, Denda T, et al. REVERCE: a randomized phase Ⅱ study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients [J]. Ann Oncol, 2019, 30(2): 259-265.
3	Hong YS, Kim SY, Lee JS, et al. Oxaliplatin-Based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial [J]. J Clin Oncol, 2019, 37(33): 3111-3123.
4	Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial [J]. Lancet Oncol, 2014, 15(10): 1065-1075.
5	Boyle T, Fritschi L, Platell C, et al. Lifestyle factors associated with survival after colorectal cancer diagnosis [J]. Br J Cancer, 2013, 109(3): 814-822.
6	萧志, 昊肖瑶, 卢晓丹. 环状RNA作为生物标志物在结直肠癌发生发展及预后中的作用 [J]. 中国肿瘤生物治疗杂志, 2019, 26(1): 116-120.
7	Chu C, Yao C, Chang Y, et al. Gene expression profiling of colorectal tumors and normal mucosa by microarrays meta-analysis using prediction analysis of microarray, artificial neural network, classification, and regression trees [J]. Dis Markers, 2014, 2014(1): 1-11.
8	Lee Y, Wei Y, Tian Y, et al. Overexpression of transcobalamin 1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy [J]. J Cancer, 2017, 8(8): 1330-1337.
9	解彤彤, 胡静, 杨觅, 等. PD-1/PD-L1在dMMR/MSI-H结直肠癌患者临床试验中的研究进展 [J]. 现代肿瘤医学, 2019, 27(5): 885-888.
10	Grzybowski A. Low serum vit. B12 level does not mean vit. B12 deficiency-problems related to the diagnosis of vitamin B12 deficiency [J]. Curr Eye Res, 2014, 39(4): 425-426.
11	Ozsoylu S. Vit B12 treatment [J]. Eur J Pediatr, 2012, 171(4): 737-739.
12	Zhao YL, Zhong SR, Zhang SH, et al. UBN2 promotes tumor progression via the Ras/MAPK pathway and predicts poor prognosis in colorectal cancer [J]. Cancer Cell Int, 2019, 19: 126.
13	王凌云, 刘小芳, 杜涛, 等. 恶性肿瘤血清叶酸、维生素B12水平测定的临床意义 [J]. 重庆医学, 2013, 42(16): 1870-1871.
14	Kudo H, Ohshio G, Ogawa K, et al. Distribution of vitamin B12 R-binder in carcinomas of the digestive tract [J]. J Clin Pathol, 1988, 41(3): 320-323.
15	Chong LY, Cheok PY, Tan W, et al. Keratin 15, Transcobalamin 1 and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification [J]. Breast Cancer Res Treat, 2012, 132(1): 143-151.
16	Wang Y, Yue C, Fang J, et al. Transcobalamin 1: a novel prognostic biomarker of neoadjuvant chemotherapy in locally advanced hypopharyngeal squamous cell cancers [J]. Onco Targets Ther, 2018, 11: 4253-4261.
17	Zhao L, Wei Y, Song A, et al. Association study between genome-wide significant variants of vitamin B12 metabolism and gastric cancer in a han Chinese population [J]. Iubmb Life, 2016, 68(4): 303-310.
18	Huang T, Xu C, Xiao J, et al. Determination of the optimal detection time of circulating tumor cells for the postoperative monitoring of colorectal cancer [J]. Oncol Lett, 2020, 19(4): 2996-3002.
19	Martinelli M, Scapoli L, Mattei G, et al. A candidate gene study of one-carbon metabolism pathway genes and colorectal cancer risk [J]. Br J Nutr, 2013, 109(6): 984-989.
20	Feodorova Y, Tashkova D, Koev I, et al. Novel insights into transcriptional dysregulation in colorectal cancer [J]. Neoplasma, 2018, 65(3): 415-424.
21	Waibel R, Treichler H, Schaefer NG, et al. New derivatives of vitamin B12 show preferential targeting of tumors [J]. Cancer Res, 2008, 68(8): 2904-2911.
22	Liu GJ, Wang YJ, Yue M, et al. High expression of TCN1 is a negative prognostic biomarker and can predict neoadjuvant chemosensitivity of colon cancer [J]. Sci Rep, 2020, 10(1): 11951-11962.

项目	例数	TCN1表达状态		χ²值	P值
项目	例数	阳性	阴性	χ²值	P值
性别				0.274	0.601
男	105	77	28
女	107	75	32
年龄				0.783	0.376
＜60岁	95	71	24
≥60岁	117	81	36
肿瘤位置				5.538	0.019
右半结肠	107	69	38
左半结肠	105	83	22
消化道病史				1.379	0.240
无	109	82	27
有	103	70	33
吸烟史				3.347	0.068
无	99	65	34
有	113	87	26
饮酒史				0.437	0.512
无	103	76	27
有	109	76	33
消化道梗阻				0.376	0.540
无	136	87	49
有	66	55	11
T分期				13.026	0.005
T1	3	1	2
T2	15	6	9
T3	50	33	17
T4	144	112	32
N分期				10.501	0.005
N0	127	82	45
N1	71	56	15
N2	14	14	0
M分期				9.201	0.002
M0	191	131	60
M1	21	21	0
TNM分期				22.446	＜0.001
Ⅰ期	18	6	12
Ⅱ期	107	74	33
Ⅲ期	67	52	15
Ⅳ期	20	20	0
病理类型				0.663	0.319
腺癌	168	123	45
黏液腺癌	14	7	7
其他类型	30	22	8
肺组织				1.086	0.025
肺转移组织	37	37	0
正常肺组织	37	6	31

项目	例数	TCN1表达状态		χ²值	P值
项目	例数	阳性	阴性	χ²值	P值
性别				0.274	0.601
男	105	77	28
女	107	75	32
年龄				0.783	0.376
＜60岁	95	71	24
≥60岁	117	81	36
肿瘤位置				5.538	0.019
右半结肠	107	69	38
左半结肠	105	83	22
消化道病史				1.379	0.240
无	109	82	27
有	103	70	33
吸烟史				3.347	0.068
无	99	65	34
有	113	87	26
饮酒史				0.437	0.512
无	103	76	27
有	109	76	33
消化道梗阻				0.376	0.540
无	136	87	49
有	66	55	11
T分期				13.026	0.005
T1	3	1	2
T2	15	6	9
T3	50	33	17
T4	144	112	32
N分期				10.501	0.005
N0	127	82	45
N1	71	56	15
N2	14	14	0
M分期				9.201	0.002
M0	191	131	60
M1	21	21	0
TNM分期				22.446	＜0.001
Ⅰ期	18	6	12
Ⅱ期	107	74	33
Ⅲ期	67	52	15
Ⅳ期	20	20	0
病理类型				0.663	0.319
腺癌	168	123	45
黏液腺癌	14	7	7
其他类型	30	22	8
肺组织				1.086	0.025
肺转移组织	37	37	0
正常肺组织	37	6	31

项目	例数	5年生存率（%）	HR值	95%CI	P值
性别			0.968	0.648~1.448	0.876
男	105	63.81
女	107	65.42
年龄			0.997	0.981~1.014	0.754
＜60岁	107	60.78
≥60岁	105	68.18
肿瘤部位			0.803	0.537~1.201	0.285
右半结肠	107	57.14
左半结肠	105	71.96
消化道病史			0.746	0.472~1.179	0.209
无	109	60.55
有	103	68.93
吸烟史			0.754	0.479~1.187	0.223
无	109	60.61
有	103	68.14
饮酒史			0.785	0.499~1.235	0.295
无	103	61.17
有	109	67.89
消化道梗阻			0.558	0.268~1.162	0.119
无	136	61.93
有	66	77.78
病理类型			0.789	0.519~1.073	0.131
腺癌	168	64.29
黏液腺癌	14	66.67
其他	30	65.52
T分期			1.128	0.833~1.529	0.437
T1	3	100.00
T2	15	66.67
T3	50	68.00
T4	144	62.50
N分期			1.117	0.815~1.532	0.491
N0	127	68.50
N1	71	56.34
N2	14	71.43
M分期			1.878	1.044~3.380	0.035
M0	191	42.86
M1	21	67.02
TNM分期			1.236	0.951~1.608	0.014
Ⅰ	18	72.22
Ⅱ	107	67.29
Ⅲ	67	65.67
Ⅳ	20	40.00
TCN1表达			1.560	0.961~2.534	0.042
阳性	152	76.67
阴性	60	59.87

项目	例数	5年生存率（%）	HR值	95%CI	P值
性别			0.968	0.648~1.448	0.876
男	105	63.81
女	107	65.42
年龄			0.997	0.981~1.014	0.754
＜60岁	107	60.78
≥60岁	105	68.18
肿瘤部位			0.803	0.537~1.201	0.285
右半结肠	107	57.14
左半结肠	105	71.96
消化道病史			0.746	0.472~1.179	0.209
无	109	60.55
有	103	68.93
吸烟史			0.754	0.479~1.187	0.223
无	109	60.61
有	103	68.14
饮酒史			0.785	0.499~1.235	0.295
无	103	61.17
有	109	67.89
消化道梗阻			0.558	0.268~1.162	0.119
无	136	61.93
有	66	77.78
病理类型			0.789	0.519~1.073	0.131
腺癌	168	64.29
黏液腺癌	14	66.67
其他	30	65.52
T分期			1.128	0.833~1.529	0.437
T1	3	100.00
T2	15	66.67
T3	50	68.00
T4	144	62.50
N分期			1.117	0.815~1.532	0.491
N0	127	68.50
N1	71	56.34
N2	14	71.43
M分期			1.878	1.044~3.380	0.035
M0	191	42.86
M1	21	67.02
TNM分期			1.236	0.951~1.608	0.014
Ⅰ	18	72.22
Ⅱ	107	67.29
Ⅲ	67	65.67
Ⅳ	20	40.00
TCN1表达			1.560	0.961~2.534	0.042
阳性	152	76.67
阴性	60	59.87

[1]	Kang Ying, Canying Yang, Fengzhen Liu, Lili Chen, Yanna Liu. Prognostic value of left ventricular myocardial strain in asymptomatic patients with severe aortic stenosis [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(06): 581-587.
[2]	Xiaoli Yi, Shasha Hu, Yan Zhang. Impact of HER-2 low expression on response of neoadjuvant chemotherapy and prognosis in breast cancer patients [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 340-346.
[3]	Jie Shi, Yuntao Li, Haiyan Gao. Prognosis of node-positive luminal A breast cancer patients with neoadjuvant and adjuvant chemotherapy and influencing factors [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 353-361.
[4]	Siping Zhang, Wei Liu, Pengcheng Ma. Therapeutic effects of lower extremity mild varus alignment after total knee arthroplasty [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 808-817.
[5]	Qian Yang, Cuifang Li, Wanqiu Zhang. Analysis of short-term and long-term prognosis and influencing factors of primary liver cancer with spontaneous ruptured hemorrhage after emergency TACE surgery [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 33-36.
[6]	Yansong Li, Huimin Feng, Mingchao Liu, Zepeng Liu, Qiuxia Jiang. Expression and clinical significance of STIP1 in triple negative breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 52-56.
[7]	Zhenjian Jiang, Ming Jiang, Dali Huang. The expression and prognostic value of TK1 and Ki67 proteins in differentiated thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 623-626.
[8]	Qingyan Yan, Xiaomei Yong, Hong Luo, Min Du. Prognostic factors and survival analysis of multicenter elderly patients with metastatic breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 636-638.
[9]	Xin Lu, Jiayi Xu, Yang Liu, Qin Yang, Wenwen Ju, Yinglong Xu. Comparison of the effects of early LC and PTCD continuous LC on liver function and prognosis of patients with acute cholecystitis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 648-650.
[10]	Ming Jiang, Rui Luo, Chengchao Long. Diagnosis and treatment of obturator hernia: An experience of 73 cases over 10 years [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(06): 706-710.
[11]	Yanjun Lu, Jian Ma, Pengyu Bai, Linghong Guo, Haiyi Liu, Bo Jiang, Wenqi Bai, Yixun Zhang. Clinical effect of Nano-carbon on 253 groups of lymph node dissection in laparoscopic radical resection of rectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 473-477.
[12]	Guangjun Zhong, Chunhua Liu, Wansen Zhu, Xiaolei Xu, Zhaojun Wang. Application of conventional MRI combined with different scanning sequences in preoperative staging diagnosis, chemotherapy efficacy and prognosis evaluation of gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 378-382.
[13]	Yongsheng Li, Jiahe Sun, Shuwei Guo, Yikang Lu, Hongzhou Liu. Short-term postoperative complications and their influencing factors in elderly patients with colorectal cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(9): 962-967.
[14]	Jun Wang, Kunpeng Liu, Lan Yao, Hua Zhang, Yue Wei, Libin Suo, Jun Chen, chengli Miao, Chenghua Luo. Retrospective analysis of anesthesia management of massive transfusion patients undergoing retroperitoneal tumor resection [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 844-849.
[15]	Libin Suo, Kunpeng Liu, Lan Yao, Hua Zhang, Yue Wei, Jun Wang, Jun Chen, Chengli Miao, Chenghua Luo. Key points of anesthesia management and prognostic factors in patients undergoing primary retroperitoneal paraganglioma resection [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 771-776.

Please choose a citation manager

Content to export